Aurinia Pharmaceuticals Inc. Stock

Price

Target price

/ Tradegate WKN: A1W7D4 / Name: Aurinia Pharma / Stock / Biotechnology & Medical Research / Small Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Aurinia Pharmaceuticals Inc. Stock

We can see a decrease in the price for Aurinia Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.092 (-1.410%).

With 1 Sell predictions and 0 Buy predictions the community sentiment towards the Aurinia Pharmaceuticals Inc. stock is not clear.

On the other hand, the target price of 10 € is above the current price of 6.58 € for Aurinia Pharmaceuticals Inc., so the potential is actually 51.98%.

So far the community has only identified positive things for Aurinia Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

What does Aurinia Pharma do?

Pros and Cons of Aurinia Pharmaceuticals Inc. in the next few years

Pros

W********* I********* f** t** n*** y****

C******** o* t** e**********

M***** P*******

Cons

B****

S********** s********

G***** c******* t* c**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Aurinia Pharmaceuticals Inc. vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Aurinia Pharmaceuticals Inc.
Promis Neurosciences Inc.
InMed Pharmaceuticals Inc.
Resverlogix Corp

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-05-02

Upon a first glance at the financials of Aurinia Pharma, a company within the Biotechnology & Medical Research industry, it is clear that they have experienced fluctuations within their financial performance over the past few years. The company's balance sheet, cash flow, and income statement show some promising elements, as well as a few areas of concern.

*Pros: *

Growing Total Assets and Stockholder Equity: Over the past three years, Aurinia Pharma has seen a steady growth in their total assets, from $463.66 million in 2020 to $470.86 million in 2022. This growth signifies an expanding company, which is a positive sign for investors. Additionally, the total stockholder equity has increased from $407.75 million in 2020 to $405.43 million in 2022, highlighting a robust financial foundation for the company.

Feedback